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Introduction {#jcsm12199-sec-0005}
============

Cancer‐related fatigue (CRF) is characterized by significant physical, emotional, and/or cognitive exhaustion, which is disproportionate to the activity level and interferes with usual functioning in patients with cancer.[1](#jcsm12199-bib-0001){ref-type="ref"} Cancer‐related fatigue is one of the most prevalent symptoms experienced by patients with cancer, both during and after treatment.[2](#jcsm12199-bib-0002){ref-type="ref"}, [3](#jcsm12199-bib-0003){ref-type="ref"} Although advances are being made, the aetiology of CRF is not yet fully understood, and treatment is mostly symptomatic.[4](#jcsm12199-bib-0004){ref-type="ref"}, [5](#jcsm12199-bib-0005){ref-type="ref"} The pathophysiology of CRF is determined by central and peripheral aspects of fatigue.[4](#jcsm12199-bib-0004){ref-type="ref"}, [6](#jcsm12199-bib-0006){ref-type="ref"}, [7](#jcsm12199-bib-0007){ref-type="ref"} Pro‐inflammatory effects of cancer result in direct changes in the muscle metabolism, leading to reduced adenosine triphosphate levels, reduced protein synthesis, and localized electrolyte imbalances causing peripheral CRF.[6](#jcsm12199-bib-0006){ref-type="ref"} Central effects of elevated cytokine levels (among which interleukin‐2, interleukin‐6, and tumour necrosis factor alpha) cause changes in activity of the hypothalamus‐pituitary‐adrenal axis, leading to a sensation of reduced capacity to perform physical work, but also to a reduced androgen expression.[6](#jcsm12199-bib-0006){ref-type="ref"}, [8](#jcsm12199-bib-0008){ref-type="ref"} Both pathways could result in a loss of muscle mass, but whether a decreased muscle mass itself affects CRF is unclear.[4](#jcsm12199-bib-0004){ref-type="ref"}, [9](#jcsm12199-bib-0009){ref-type="ref"}

Promising results for the treatment of CRF are seen with exercise interventions.[10](#jcsm12199-bib-0010){ref-type="ref"}, [11](#jcsm12199-bib-0011){ref-type="ref"}, [12](#jcsm12199-bib-0012){ref-type="ref"} Exercise interventions can improve muscle mass, strength, and functioning, depending on the type and intensity of exercise. Which type of exercise (e.g. aerobic, resistance), and at which intensity level, contributes most to the positive effect on CRF is not yet fully known[4](#jcsm12199-bib-0004){ref-type="ref"}, [12](#jcsm12199-bib-0012){ref-type="ref"}, [13](#jcsm12199-bib-0013){ref-type="ref"} and neither is the pathophysiological mechanism of this effect. Several studies have been performed investigating the effect of exercise interventions on CRF in patients with limited disease, and their results indicate improvement of CRF and increased muscle mass, but the effect sizes varied.[14](#jcsm12199-bib-0014){ref-type="ref"}, [15](#jcsm12199-bib-0015){ref-type="ref"}, [16](#jcsm12199-bib-0016){ref-type="ref"}, [17](#jcsm12199-bib-0017){ref-type="ref"}, [18](#jcsm12199-bib-0018){ref-type="ref"} In these trials, the association between muscle mass and CRF was not studied. Current data on the association between muscle mass and CRF are scarce and conflicting.[19](#jcsm12199-bib-0019){ref-type="ref"}, [20](#jcsm12199-bib-0020){ref-type="ref"}

In this study, we aim to accurately define to what extent muscle mass is related to CRF in patients with advanced cancer. We performed a cross‐sectional study of the association between muscle mass and CRF in patients with advanced cancer. A direct relation between muscle mass and CRF would further support the hypothesis that improving muscle mass is an important target for reducing CRF.

Methods {#jcsm12199-sec-0006}
=======

A cross‐sectional study was performed in patients with advanced cancer scheduled for treatment with chemotherapy between June 2011 and July 2014. This study was embedded in a large observational study in patients with advanced cancer (Netherlands trial register NTR3094), which resulted in two publications.[21](#jcsm12199-bib-0021){ref-type="ref"}, [22](#jcsm12199-bib-0022){ref-type="ref"} Patients with colorectal, breast, prostate, or lung cancer, normal blood counts, and no chemistry abnormalities who were scheduled to start a new line of chemotherapy were included in this trial. Exclusion criteria were peripheral edema or ascites, chemotherapy in the previous month, pregnancy, and insufficient comprehension of the Dutch language to complete questionnaires. After providing informed consent, patient characteristics and data on comorbidity and prior treatments were collected from the patients\' medical files. All data were anonymized and stored in the web‐based database system Open Clinica (version 3.3). This observational study was approved by the ethics committee of the VU University medical center.

Assessments {#jcsm12199-sec-0007}
-----------

Fatigue was assessed with the Functional Assessment of Chronic Illness Therapy (FACIT)‐fatigue.[23](#jcsm12199-bib-0023){ref-type="ref"} The FACIT‐fatigue is a validated questionnaire focusing on physical fatigue and the functional consequences of fatigue. It has an excellent internal consistency (Cronbach\'s alpha 0.93--0.95) and good test--retest reliability (*r* 0.72--0.90).[23](#jcsm12199-bib-0023){ref-type="ref"}, [24](#jcsm12199-bib-0024){ref-type="ref"}, [25](#jcsm12199-bib-0025){ref-type="ref"} The 13 items are scored on a 4‐point Likert scale, resulting in a total score between 0 and 52 points, with lower scores indicating higher levels of CRF. A score \<34 on the FACIT‐fatigue was previously defined as a cut‐off for fatigue.[26](#jcsm12199-bib-0026){ref-type="ref"}, [27](#jcsm12199-bib-0027){ref-type="ref"} This cut‐off is concordant with the ICD‐10 criteria for CRF, which state that significant fatigue, diminished energy, and an increased need to rest (disproportionate to any recent change in activity level) should be present during at least two consecutive weeks in the past month, or that one or two of these symptoms are present combined with five or more out of 10 other symptoms that directly influence daily activities.[27](#jcsm12199-bib-0027){ref-type="ref"}

Skeletal muscle area (cm^2^) was measured with SliceOmatic Software V 5.0 (Tomovision, Magog, Canada) using routine computed tomography (CT) scans conducted for diagnostic purposes before start of chemotherapy treatment. The third lumbar vertebra (L3) was used as a standard landmark.[28](#jcsm12199-bib-0028){ref-type="ref"}, [29](#jcsm12199-bib-0029){ref-type="ref"} The first image extending from L3 to the iliac crest was chosen to measure total muscle cross‐sectional area. The L3 region contains psoas, para‐spinal muscles (erector spinae, quadratus lumborum), and the abdominal wall muscles (transversus abdominus, external and internal obliques, rectus abdominus). These muscles were identified based on their anatomic features by a trained researcher. The structures of those specific muscles were quantified based on pre‐established thresholds of Hounsfield Units (HU) (−29 to +150) of skeletal muscle tissue.[30](#jcsm12199-bib-0030){ref-type="ref"} Cross‐sectional areas (cm^2^) of the sum of all these muscles were computed by summing tissue pixels and multiplying by the pixel surface area. In patients with lung cancer, no routine CT scan of the abdomen including L3 is being made. Therefore, there were no CT images available on level L3 for the lung cancer patients; T4 was used as an alternative for the assessment of the skeletal muscle area. This region contains pectoral muscles, external intercostal, serratus anterior, teres major, subscapularis, infraspinatus, rhomboid major, erector spinae, and trapezius muscles. Measurements at the T4 level are currently being validated; therefore, these results were analysed separately and should be interpreted with caution.

Skeletal muscle index (SMI) was calculated as the ratio of skeletal muscle area (cm^2^)/height (m)^2^. Body height was measured using a stadiometer; the patient was standing barefoot, and height was determined to the nearest cm. Low SMI on level L3 was defined as \<41cm^2^/m^2^ for women, \<43 cm^2^/m^2^ for men with a body mass index (BMI) \<25 kg/m^2^, and \<53 cm^2^/m^2^ for men with BMI ≥25 kg/m^2.^ [31](#jcsm12199-bib-0031){ref-type="ref"} For level T4 no reference values are available.

Statistical analysis {#jcsm12199-sec-0008}
--------------------

Descriptive results are presented by their mean and standard deviation, or median and interquartile range (IQR) whenever appropriate. Univariate and multiple linear regression were used study the association between CRF and SMI, adjusted for age; gender; tumour type; chemotherapy treatment line (first vs. second and higher); Charlson Comorbidity Index; and chemotherapy, hormone therapy, targeted therapy, or high dose corticosteroid treatment (equivalent to prednisone \>10 mg/day over 3 weeks) in the past 6 months. These factors were chosen as they may influence CRF and/or SMI.[32](#jcsm12199-bib-0032){ref-type="ref"}, [33](#jcsm12199-bib-0033){ref-type="ref"} To study whether the association between SMI and fatigue was modified by age, gender, and hormone therapy, we added the interaction terms of SMI with these variables into the regression equation. All statistical tests were two sided, and *P* \< 0.05 was considered statistically significant. Analyses were performed with IBM SPSS version 22.0.0.0 (IBM, Armonk, NY, USA).

Results {#jcsm12199-sec-0009}
=======

In total, 302 patients were included, of whom 233 patients had both completed the FACIT‐fatigue questionnaire and had a CT scan that met the required conditions for assessment of the skeletal muscle area (*Figure* [1](#jcsm12199-fig-0001){ref-type="fig"}). The L3 group (*n* = 151) comprised patients with colorectal, prostate, and breast cancer. The T4 group (*n* = 82) comprised patients with lung cancer. Patients were included with a CT scan within 90 days of their assessment; however, approximately 80% of the patients had a CT scan made within the last 30 days as was considered appropriate for their cancer treatment by their oncologist. The median number of days between the CT scan and FACIT‐fatigue scoring was 15 days (IQR 7--28). Patient characteristics are shown in *Table* [1](#jcsm12199-tbl-0001){ref-type="table-wrap"}.

![Study flow chart.](JCSM-8-623-g001){#jcsm12199-fig-0001}

###### 

Patient characteristics

  --------------------------------------------------------------------------------------------------
                                                         All patients\   L3 group\     T4 group\
                                                         *n* = 233\      *n* = 151\    *n* = 82\
                                                         *n* (%)         *n* (%)       *n* (%)
  ---------------------------------------- ------------- --------------- ------------- -------------
  Age                                          Mean (SD) 63.6 (9.9)      64.5 (9.8)    61.9 (9.9)

  Gender                                           Male\ 129 (55)\       89 (59)\      40 (49)\
                                                  Female 104 (45)        62 (41)       42 (51)

  Cancer type                                      Lung\ 82 (35)\        ---\          82 (100)\
                                             Colorectal\ 75 (32)\        75 (50)\      ---\
                                               Prostate\ 44 (19)\        44 (29)\      ---\
                                                  Breast 32 (14)         32 (21)       ---

  Brain metastasis                                       18 (8)          3 (2)         15 (18)

  Chemotherapy in past 6 months                          35 (15)         26 (17)       9 (11)

  Radiotherapy in past 6 months                          9 (4)           3 (2)         6 (7)

  Hormone therapy in past 6 months                       31 (13)         31 (21)       0 (0)

  Targeted therapy in past 6 months                      18 (8)          14 (9)        4 (5)

  Corticosteroid use in past 6 months^1^                 24 (10)         16 (11)       8 (10)

  ECOG performance status                             0\ 57 (25)\        46 (31)\      11 (13)\
                                                      1\ 94 (40)\        83 (55)\      11 (13)\
                                                      2\ 17 (7)\         14 (9)\       3 (4)\
                                                 Unknown 65 (28)         8 (5)         57 (70)

  Charlson Comorbidity Index^2^                       0\ 165 (71)\       112 (74)\     53 (65)\
                                                   1--2\ 62 (27)\        35 (23)\      27 (33)\
                                                   3--4\ 4 (2)\          3 (2)\        1 (1)\
                                                      ≥5 2 (1)           1 (1)         1 (1)

  Chemotherapy line                               First\ 183 (79)\       114 (76)\     69 (84)\
                                                 Second\ 32 (14)\        24 (16)\      8 (10)\
                                                  Third\ 10 (4)\         7 (5)\        3 (4)\
                                                 \>Third 8 (3)           6 (4)         2 (2)

  C‐reactive proteine (mg/L)                     Median\ 12 (4--33)      9 (4--28)     13 (4--35)
                                                   (IQR)                               

  Albumin (g/L)                                Mean (SD) 35 (4)          36 (4)        35 (5)

  Haemoglobin (mmol/L)                         Mean (SD) 8.0 (1.0)       7.9 (1.0)     8.2 (1.0)

  Creatinin (μmol/L)                             Median\ 68 (57--83)     68 (58--83)   70 (59--84)
                                                   (IQR)                               

  BMI (kg/m^2^)                                Mean (SD) 25.6 (4.0)      26.2 (3.8)    24.6 (4.1)

  BMI males (kg/m^2^)                          Mean (SD) 26.0 (3.7)      26.6 (3.4)    24.7 (4.1)

  BMI females (kg/m^2^)                        Mean (SD) 25.1 (4.3)      25.6 (4.3)    24.4 (4.2)
  --------------------------------------------------------------------------------------------------

Characteristics of the patients included in the study. BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range (25th and 75th percentile); SD, standard deviation of the mean.

1\. \>10 mg prednisolon/day for at least 3 weeks.

2\. Charlson Comorbidity Index, not adjusted for age, primary cancer diagnosis was not counted as comorbidity.

The median score on the FACIT‐fatigue questionnaire was 36 (IQR 26--44); 96 patients (41%) were diagnosed with CRF (FACIT‐fatigue score \<34, *Table* [2](#jcsm12199-tbl-0002){ref-type="table-wrap"}). The median SMI was 43 cm^2^/m^2^ in the L3 group and 59 cm^2^/m^2^ in the T4 group (*Table* [2](#jcsm12199-tbl-0002){ref-type="table-wrap"}). In the L3 group, 58% of the men and 61% of the women had a low SMI.

###### 

SMI and FACIT‐fatigue scores

                  Skeletal muscle area (cm^2^) median (IQR)   Skeletal muscle index (cm^2^/m^2^) median (IQR)   FACIT‐fatigue score median (IQR)   FACIT‐fatigue score \< 34 n (%)                                                                
  -------------- ------------------------------------------- ------------------------------------------------- ---------------------------------- --------------------------------- ------------- ------------- ------------- --------- --------- ---------
  Total group                  177 (149--210)                                 133 (109--153)                              59 (53--69)                        43 (38--50)             36 (26--44)   35 (23--43)   38 (29--45)   96 (41)   37 (45)   59 (39)
  T4 *n* = 82                                                                                                                                                                                                                                     
  L3 *n* = 151                                                                                                                                                                                                                                    
  Men                          208 (189--236)                                 148 (133--167)                              67 (59--73)                        46 (42--52)             38 (26--45)   33 (21--41)   40 (31--47)   49 (38)   20 (50)   29 (33)
  T4 *n* = 40                                                                                                                                                                                                                                     
  L3 *n* = 89                                                                                                                                                                                                                                     
  Women                        153 (132--165)                                 108 (101--124)                              55 (51--62)                        39 (36--45)             36 (25--43)   37 (25--44)   34 (27--43)   47 (45)   17 (41)   30 (48)
  T4 *n* = 42                                                                                                                                                                                                                                     
  L3 *n* = 62                                                                                                                                                                                                                                     

FACIT, Functional Assessment of Chronic Illness Therapy; IQR, interquartile range; SMI, skeletal muscle index.

Skeletal muscle data and FACIT‐fatigue scores of the patients included in the study. Data are presented for the entire group and separately for patients with a CT scan on the level of the third lumbar or fourth thoracic vertebrae, and for men and women separately. For the FACIT‐fatigue questionnaire, a score below 34 points correlates with clinically significant fatigue.

The univariate association between SMI and CRF in the L3 group had a B of 0.230 (95% CI −0.004--0.464, *P* 0.054) (*Figure* [2](#jcsm12199-fig-0002){ref-type="fig"} and *Table* [3](#jcsm12199-tbl-0003){ref-type="table-wrap"}). In the multivariate analysis, this association was modified by gender (*B* ~interaction~ 0.716, 95% CI 0.172--1.261, *P* 0.010). Age and hormone therapy did not modify the association between SMI and CRF. Subsequent stratified analysis showed a statistically significant positive association between SMI and CRF in men (*B* 0.345, 95% CI 0.017--0.672, *P* 0.039) in the L3 group. In women (*n* = 62), higher SMI seemed to be associated with more CRF, but this was not statistically significant (*B* −0.401, 95% CI −0.867--0.065, *P* 0.090) (*Table* [3](#jcsm12199-tbl-0003){ref-type="table-wrap"}). No significant association between SMI and CRF was found in the T4 group (*B* 0.082, 95% CI −0.167--0.330, *P* 0.515). The association between SMI and CRF in the T4 group was modified by age (*B* ~interaction~ 0.024, 95% CI 0.005--0.043, *P* 0.014). Skeletal muscle index and CRF were not associated in any of the stratified analyses \[several subgroups were defined: split at median age (61.9), and three groups age \< 50, 50--70, and \>70\].

![Correlation of skeletal muscle index (SMI) and Functional Assessment of Chronic Illness Therapy (FACIT)‐fatigue.](JCSM-8-623-g002){#jcsm12199-fig-0002}

###### 

Univariate and multivariate linear analysis

  Study sample       B        95% CI lower bound   95% CI upper bound   Sign.
  ------------------ -------- -------------------- -------------------- -------
  L3---Total group                                                      
  Univariate         0.230    −0.004               0.464                0.054
  Multivariate       0.142    −0.118               0.403                0.282
  L3---Men                                                              
  Univariate         0.447    0.143                0.751                0.004
  Multivariate       0.345    0.017                0.672                0.039
  L3---Women                                                            
  Univariate         −0.422   −0.856               0.012                0.056
  Multivariate       −0.401   −0.867               0.065                0.090
  T4---Total group                                                      
  Univariate         0.065    −0.139               0.269                0.530
  Multivariate       0.082    −0.167               0.330                0.515

Univariate and multivariate analysis studying the association between skeletal muscle index (SMI) and Functional Assessment of Chronic Illness Therapy (FACIT)‐fatigue scores. Multivariate analysis was performed with the following covariates: sex (L3‐total group and T4 group); age; tumour type (L3 group); chemotherapy\*; hormone therapy\*; targeted therapy\*; corticosteroid treatment (\>10 mg prednisolon/day for at least 3 weeks); first vs. ≥second line of chemotherapy; and Charlson Comorbidity Index (not age adjusted).

As prior treatment in the past six months.

Discussion {#jcsm12199-sec-0010}
==========

Cancer‐related fatigue is a highly prevalent symptom that deteriorates quality of life. Both the current concepts of the multifactorial pathophysiology of CRF and the efficacy of training interventions support the hypothesis that muscle wasting is associated with CRF. In the current study, 41% of the patients were diagnosed with CRF, and more than half of the patients in the L3 group had a low SMI.[31](#jcsm12199-bib-0031){ref-type="ref"} We found a significant association between higher muscle mass assessed at level L3 and lower fatigue levels in men, but not in women.

The significant association between muscle mass at level L3 and CRF in men is in line with a previous study by Kilgour *et al.* [20](#jcsm12199-bib-0020){ref-type="ref"} who performed a cross‐sectional study among 84 patients with inoperable (stage III--IV) gastro‐intestinal or non‐small cell lung cancer. Kilgour *et al.* have found a significant univariate negative correlation (*B* − 4.8, *P* \< 0.01) between fatigue measured with the Brief Fatigue Inventory and muscle mass measured with dual‐energy X‐ray absorptiometry (skeletal muscle mass index). In the multivariate analysis, the association between muscle mass and fatigue was modified by gender. Subgroup analysis showed that fatigue scores had a strong negative correlation with muscle mass in men (*r* 0.60, *P* \< 0.001) but not in women. In the current study, we were able to confirm these results in a larger group of patients with more diverse tumour types, while using other, also well‐validated instruments to measure CRF and muscle mass. Kilgour *et al.* suggested that the different results for men and women were possibly related to absolute differences in muscle mass between men and women, or differences in BMI or circulating sex hormones. In the current study, the median muscle mass index for men in the L3 group is on the lower end of the skeletal muscle mass index range in the study by Kilgour *et al.* when using the equation provided by Mourtzakis *et al.*,[29](#jcsm12199-bib-0029){ref-type="ref"} but still a relation with fatigue is found in these men. The lower SMI of women is therefore possibly not the only explanation for this result. Body mass index did also not differ between the men and women in the L3 group in the current study. No measurements of sex hormones were performed in the current study. Approximately half of the males in the L3 group were diagnosed with prostate cancer and were pretreated with androgen deprivation therapy, but the diagnosis of prostate cancer was not a predictive factor for fatigue.

Muscle mass and fatigue for women in the L3 group were not only unrelated, but we even found a trend towards higher fatigue levels in women with higher muscle mass. Almost half of these women were diagnosed with breast cancer and frequently pretreated with hormone or chemotherapy, which may have resulted in a selection bias for women with less fatigue, or who have already participated in exercise programs during/after previous treatment lines.

An important strength of this study is the use of reliable, validated instruments to assess CRF[23](#jcsm12199-bib-0023){ref-type="ref"}, [24](#jcsm12199-bib-0024){ref-type="ref"} as well as the objective assessment of muscle mass[34](#jcsm12199-bib-0034){ref-type="ref"} in a relatively large group of patients with advanced cancer. Although the assessment of muscle mass at L3 level is well validated,[35](#jcsm12199-bib-0035){ref-type="ref"} muscle mass assessment at T4 level needs validation. No correlation between muscle mass and fatigue was present in the T4 group. Although this result might be influenced by a limited sample size in the gender specific subgroups or differences in tumour types, it could also be possible that the measurement of muscle mass at level T4 is less reliable.

A possible limitation from our study is the fact that most likely other factors influence fatigue in patients with advanced cancer. In the current study, the effect of pain and distress, which can also influence fatigue scores,[1](#jcsm12199-bib-0001){ref-type="ref"} was not evaluated. Furthermore, central aspects of CRF, such as the effect of serotonin and cortisol levels on the functioning of the suprachiasmatic nucleus, may play a major role in its severity, independent from their effect on muscle mass.[4](#jcsm12199-bib-0004){ref-type="ref"} The positive effect of endurance exercise on CRF may be related to these central effects.[6](#jcsm12199-bib-0006){ref-type="ref"} The study of Lovgren *et al.* in lung cancer patients also suggests that women experience more problems with emotional functioning than men, which may also result in higher levels of fatigue.[36](#jcsm12199-bib-0037){ref-type="ref"}

Second, we may have included a relatively fit group of patients with a good performance status and low comorbidity. Therefore, patients with an extremely low SMI or high fatigue levels may have been excluded on forehand because of a poor performance status. This bias should be taken into account when generalizing these results to other patient groups. From the current data, it could not be extrapolated whether this may have also been a factor contributing to the absence of a correlation between SMI and CRF in women.

Third, because this is a cross‐sectional study, causality cannot be assumed. Future studies need to confirm that an increase in muscle mass actually leads to a reduced fatigue level in men with advanced cancer. This may be of major clinical importance as fatigue is one of the most common symptoms in patient with advanced cancer, for whom quality of life is generally (one of) the most important factor(s) in treatment decisions. From our perspective, patients with progressively advanced cancer do often have benefit from effective palliative chemotherapy in the sense of improving their condition by reducing their tumour burden. Combining cancer treatment with exercise and/or dietary interventions that increase muscle mass may help to further improve treatment tolerance and results.

Conclusions {#jcsm12199-sec-0011}
===========

We found a significant association between muscle mass and CRF in men with advanced cancer, but not in women. These findings may lead to the suggestion that exercising may potentially be beneficial to reduce or prevent fatigue in men by increasing muscle mass. The absence of a relation between SMI and CRF in women and the limited strength of the association in men highlight that CRF is a multifactorial problem. To further reduce CRF in both men and women with cancer, multifactorial assessments need to be performed in order to develop effective treatment strategies.
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